AbbVie
ABBV
149,68 €
Share price
1.12%
Change (1 day)
-4.98%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Revenue for AbbVie (ABBV)
Revenue in 2024 (TTM): €52.34 Billion
According to AbbVie's latest financial reports the company's current revenue (TTM 
) is €49.00 Billion. an increase over the revenue in the year 2023 that were of €49.13 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbbVie from 2011 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | €54.13 B | 10.17% |
| 2023 | €49.13 B | -9.21% |
| 2022 | €54.12 B | 9.07% |
| 2021 | €49.62 B | 33.25% |
| 2020 | €37.23 B | 25.4% |
| 2019 | €29.69 B | 3.72% |
| 2018 | €28.63 B | 21.75% |
| 2017 | €23.51 B | -3.52% |
| 2016 | €24.37 B | 16.59% |
| 2015 | €20.90 B | 27.39% |
| 2014 | €16.41 B | 20.62% |
| 2013 | €13.60 B | -2.08% |
| 2012 | €13.89 B | 3.44% |
| 2011 | €13.43 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | €55.34 B | 12.94% | 🇺🇸 USA |
 | €42.01 B | -14.26% | 🇺🇸 USA |
 | €39.18 B | -20.04% | 🇺🇸 USA |
 | €29.07 B | -40.67% | 🇺🇸 USA |
 | €25.01 B | -48.96% | 🇺🇸 USA |
 | €8.41 B | -82.82% | 🇺🇸 USA |
 | €34.95 B | -28.67% | 🇬🇧 UK |
 | €47.03 B | -4.01% | 🇬🇧 UK |
 | €2.04 B | -95.82% | 🇺🇸 USA |